Agios Pharmaceuticals, Inc. (AGIO) Income Statement
AGIO 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsAGIO revenue and net income
Where AGIO's revenue goes
2025Each bar shows an amount and its share of revenue. AGIO kept −764.0% of revenue as net income.
AGIO profit margins
AGIO growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | +48.0% | +56.0% | −23.3% | −0.9% |
| Gross profit | +31.5% | +50.2% | — | −3.2% |
| Operating income | — | — | — | — |
| Net income | −161.3% | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
AGIO quarterly EPS vs estimates
Agios Pharmaceuticals beat the analyst EPS estimate in 5 of the last 8 quarters. Next report: November 5, 2026 (estimate $-1.32).
AGIO income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $54.0M | $36.5M | $26.8M | $14.2M | $41,409 | $203.2M | $117.9M | $94.4M | $43.0M | $69.9M |
| Cost of revenue | $11.5M | $4.2M | $9.5M | $1.7M | $18.8M | $18.8M | $1.3M | $1.4M | $292.7M | $220.2M |
| Gross profit | $42.5M | $32.3M | $17.3M | $12.5M | −$18.8M | −$18.8M | $116.6M | $93.0M | $43.0M | $69.9M |
| Research & development | $334.4M | $301.3M | $288.9M | $279.9M | $257.0M | $211.0M | $410.9M | $341.3M | $292.7M | $220.2M |
| Sales, general & admin | $180.3M | $156.8M | $119.9M | $121.7M | $121.4M | $149.1M | $132.0M | $114.1M | $71.1M | $50.7M |
| Total operating expenses | $514.6M | $458.1M | $408.8M | $401.6M | $359.6M | $317.1M | $542.9M | $455.5M | $363.8M | $270.9M |
| Operating income | −$472.1M | −$425.7M | −$391.5M | −$389.0M | −$378.4M | −$335.9M | −$426.3M | −$362.5M | −$320.8M | −$201.0M |
| Interest income | $56.4M | $48.1M | $33.3M | $12.8M | $836,000 | $6.6M | $14.9M | $16.5M | $6.1M | $2.5M |
| Interest expense | — | — | — | $12.8M | $836,000 | $17.8M | $14.9M | $16.5M | $6.1M | $2.5M |
| Income before taxes | −$413.8M | $718.0M | −$352.1M | −$231.8M | −$356.5M | −$329.3M | −$411.5M | −$346.0M | −$314.7M | −$198.5M |
| Income taxes | −$1.0M | $44.2M | $6.5M | −$157.2M | −$1.98B | $7.8M | −$14.9M | $32.9M | −$6.4M | −$5.7M |
| Net income | −$412.8M | $673.7M | −$352.1M | −$231.8M | $1.60B | −$327.4M | −$411.5M | −$346.0M | −$314.7M | −$198.5M |
| EBITDA | −$408.6M | $723.6M | −$345.5M | −$223.2M | −$347.3M | −$310.5M | −$403.4M | −$355.3M | −$314.4M | −$195.3M |
| EPS (diluted) | −$7.11 | −$6.35 | −$6.34 | −$4.24 | −$5.95 | −$4.74 | −$6.87 | −$6.03 | −$6.74 | −$5.05 |
| Gross margin | 78.7% | 88.6% | 64.6% | 88.0% | −45,345.2% | −9.2% | 98.9% | 98.5% | 100.0% | 100.0% |
| Operating margin | −873.9% | −1,166.5% | −1,459.5% | −2,732.1% | −913,854.5% | −165.3% | −361.6% | −384.0% | −745.8% | −287.6% |
| Net margin | −764.0% | 1,845.9% | −1,312.6% | −1,627.8% | 3,875,280.7% | −161.1% | −349.0% | −366.6% | −731.6% | −284.0% |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $44.7M | $20.7M | $20.0M | $12.9M | $12.5M | $8.7M | $10.7M | $9.0M | $8.6M | $8.2M | $7.1M | $7.4M |
| Cost of revenue | $3.0M | $2.7M | $3.1M | $3.1M | $3.0M | $2.4M | $1.3M | $783,000 | $3.1M | $2.0M | $2.0M | $633,000 |
| Gross profit | $41.7M | $18.1M | $16.8M | $9.8M | $9.5M | $6.4M | $9.5M | $8.2M | $5.5M | $6.2M | $5.1M | $6.8M |
| Research & development | $100.8M | $79.8M | $86.8M | $85.4M | $90.7M | $71.5M | $82.8M | $72.5M | $75.8M | $67.3M | $76.1M | $81.8M |
| Sales, general & admin | $51.5M | $48.3M | $51.6M | $41.3M | $45.9M | $41.5M | $51.7M | $38.5M | $35.5M | $31.0M | $35.3M | $25.8M |
| Total operating expenses | $152.3M | $128.1M | $138.4M | $126.7M | $136.6M | $113.0M | $134.5M | $111.0M | $111.3M | $98.3M | $111.4M | $107.7M |
| Operating income | −$110.6M | −$110.0M | −$121.6M | −$116.9M | −$127.1M | −$106.6M | −$125.0M | −$102.8M | −$105.8M | −$92.1M | −$106.3M | −$100.9M |
| Interest income | $9.7M | $10.8M | $12.4M | $13.4M | $14.5M | $16.1M | $18.0M | $13.1M | $8.1M | $8.9M | $8.6M | $8.4M |
| Income before taxes | −$100.7M | −$99.1M | −$109.1M | −$103.4M | −$112.0M | −$89.3M | −$105.4M | $1.00B | −$96.1M | −$81.5M | −$95.9M | −$91.3M |
| Income taxes | — | — | −$1.0M | — | — | — | −$8.9M | $53.1M | — | $1.3M | $1.4M | −$10.0M |
| Net income | −$100.7M | −$99.1M | −$108.0M | −$103.4M | −$112.0M | −$89.3M | −$96.5M | $947.9M | −$96.1M | −$81.5M | −$95.9M | −$91.3M |
| EBITDA | −$109.2M | −$97.7M | −$107.8M | −$102.1M | −$110.8M | −$88.0M | −$104.0M | $1.00B | −$94.5M | −$80.2M | −$94.5M | −$89.7M |
| EPS (diluted) | −$1.69 | −$1.69 | −$1.85 | −$1.78 | −$1.93 | −$1.55 | −$1.74 | −$1.47 | −$1.69 | −$1.45 | −$1.72 | −$1.64 |
| Gross margin | 93.3% | 87.1% | 84.2% | 76.3% | 76.2% | 72.9% | 88.3% | 91.3% | 64.2% | 75.9% | 72.0% | 91.4% |
| Operating margin | −247.1% | −530.3% | −608.9% | −907.4% | −1,020.1% | −1,222.0% | −1,165.3% | −1,146.9% | −1,228.3% | −1,124.3% | −1,496.2% | −1,363.7% |
| Net margin | −225.1% | −477.7% | −541.1% | −803.1% | −899.4% | −1,023.3% | −899.6% | 10,574.7% | −1,115.7% | −995.8% | −1,350.7% | −1,234.3% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in AGIO's financial statements (latest annual report filed February 12, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
AGIO financial results
In fiscal year 2025 (ended December 31, 2025), Agios Pharmaceuticals reported revenue of $54.0 million, up 48.0% from the year before. It had a net loss of $412.8 million, a net profit margin of −764.0%. Diluted earnings per share came to −$7.11. Over five years revenue grew at an average rate of −23.3% a year.
See the AGIO stock overview for the latest quote and news, or the AGIO chart for price history and technical indicators.
AGIO income statement FAQ
What is Agios Pharmaceuticals's annual revenue?
Agios Pharmaceuticals reported total revenue of $54.0 million for fiscal year 2025, which ended on December 31, 2025. That was up 48.0% from $36.5 million the previous year.
Is Agios Pharmaceuticals profitable?
No. Agios Pharmaceuticals reported a net loss of $412.8 million in fiscal 2025, a net profit margin of −764.0%; its operating margin was −873.9%.
What is Agios Pharmaceuticals's gross margin?
Agios Pharmaceuticals's gross margin was 78.7% in fiscal 2025: for every $100 of revenue, Agios Pharmaceuticals kept $79 after the direct cost of its products and services.
How much does Agios Pharmaceuticals spend on research and development?
Agios Pharmaceuticals spent $334.4 million on research and development in fiscal 2025, 618.9% of revenue.
How fast is Agios Pharmaceuticals growing?
Revenue grew −23.3% a year on average over the last five fiscal years, from $203.2 million to $54.0 million.
What are Agios Pharmaceuticals's earnings per share?
Agios Pharmaceuticals earned $-7.11 per diluted share in fiscal 2025, compared with $-6.35 a year earlier.
When will Agios Pharmaceuticals report its next earnings?
Agios Pharmaceuticals is expected to report results for the quarter ending September 30, 2026 on November 5, 2026 before the market opens.
When does Agios Pharmaceuticals's fiscal year end?
Agios Pharmaceuticals's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on February 12, 2026.